91 related articles for article (PubMed ID: 29339107)
21. Casein Kinase 1α Mediates the Degradation of Receptors for Type I and Type II Interferons Caused by Hemagglutinin of Influenza A Virus.
Xia C; Wolf JJ; Vijayan M; Studstill CJ; Ma W; Hahm B
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343571
[TBL] [Abstract][Full Text] [Related]
22. A Sulfonozanamivir Analogue Has Potent Anti-influenza Virus Activity.
Hadházi Á; Li L; Bailly B; Maggioni A; Martin G; Dirr L; Dyason JC; Thomson RJ; Gao GF; Borbás A; Ve T; Pascolutti M; von Itzstein M
ChemMedChem; 2018 Apr; 13(8):785-789. PubMed ID: 29453852
[TBL] [Abstract][Full Text] [Related]
23. Life cycle synchronization is a viral drug resistance mechanism.
Neagu IA; Olejarz J; Freeman M; Rosenbloom DIS; Nowak MA; Hill AL
PLoS Comput Biol; 2018 Feb; 14(2):e1005947. PubMed ID: 29447150
[TBL] [Abstract][Full Text] [Related]
24. An "All-In-One" Pharmacophoric Architecture for the Discovery of Potential Broad-Spectrum Anti-Flavivirus Drugs.
Ncube NB; Ramharack P; Soliman MES
Appl Biochem Biotechnol; 2018 Jul; 185(3):799-814. PubMed ID: 29349531
[TBL] [Abstract][Full Text] [Related]
25. Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.
Shirley M
Drugs; 2020 Jul; 80(11):1109-1118. PubMed ID: 32601915
[TBL] [Abstract][Full Text] [Related]
26. Neuraminidase inhibitor resistance in influenza: a clinical perspective.
Lee N; Hurt AC
Curr Opin Infect Dis; 2018 Dec; 31(6):520-526. PubMed ID: 30299356
[TBL] [Abstract][Full Text] [Related]
27. Structure and Function of Influenza Virus Ribonucleoprotein.
Lo CY; Tang YS; Shaw PC
Subcell Biochem; 2018; 88():95-128. PubMed ID: 29900494
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and SARs of dopamine derivatives as potential inhibitors of influenza virus PA
Liao Y; Ye Y; Li S; Zhuang Y; Chen L; Chen J; Cui Z; Huo L; Liu S; Song G
Eur J Med Chem; 2020 Mar; 189():112048. PubMed ID: 31954881
[TBL] [Abstract][Full Text] [Related]
29. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
Noshi T; Kitano M; Taniguchi K; Yamamoto A; Omoto S; Baba K; Hashimoto T; Ishida K; Kushima Y; Hattori K; Kawai M; Yoshida R; Kobayashi M; Yoshinaga T; Sato A; Okamatsu M; Sakoda Y; Kida H; Shishido T; Naito A
Antiviral Res; 2018 Dec; 160():109-117. PubMed ID: 30316915
[TBL] [Abstract][Full Text] [Related]
30. 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies.
Kang D; Ruiz FX; Sun Y; Feng D; Jing L; Wang Z; Zhang T; Gao S; Sun L; De Clercq E; Pannecouque C; Arnold E; Zhan P; Liu X
J Med Chem; 2021 Apr; 64(7):4239-4256. PubMed ID: 33734714
[TBL] [Abstract][Full Text] [Related]
31. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses.
Ma Y; Frutos-Beltrán E; Kang D; Pannecouque C; De Clercq E; Menéndez-Arias L; Liu X; Zhan P
Chem Soc Rev; 2021 Apr; 50(7):4514-4540. PubMed ID: 33595031
[TBL] [Abstract][Full Text] [Related]
32. Focusing on the Influenza Virus Polymerase Complex: Recent Progress in Drug Discovery and Assay Development.
Zhang J; Hu Y; Musharrafieh R; Yin H; Wang J
Curr Med Chem; 2019; 26(13):2243-2263. PubMed ID: 29984646
[TBL] [Abstract][Full Text] [Related]
33. Natural Product-Derived Phytochemicals for Influenza A Virus (H1N1) Prevention and Treatment.
Li R; Han Q; Li X; Liu X; Jiao W
Molecules; 2024 May; 29(10):. PubMed ID: 38792236
[TBL] [Abstract][Full Text] [Related]
34. Recent advances of phenotypic screening strategies in the application of anti-influenza virus drug discovery.
Jia H; Hu L; Zhang J; Huang X; Jiang Y; Dong G; Liu C; Liu X; Kim M; Zhan P
RSC Med Chem; 2024 Jan; 15(1):70-80. PubMed ID: 38283223
[TBL] [Abstract][Full Text] [Related]
35. Structural Investigations of Interactions between the Influenza a Virus NS1 and Host Cellular Proteins.
Blake ME; Kleinpeter AB; Jureka AS; Petit CM
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896840
[TBL] [Abstract][Full Text] [Related]
36. Compatibility of Nucleobases Containing Pt(II) Complexes with Red Blood Cells for Possible Drug Delivery Applications.
De Castro F; Stefàno E; Fanizzi FP; Di Corato R; Abdalla P; Luchetti F; Nasoni MG; Rinaldi R; Magnani M; Benedetti M; Antonelli A
Molecules; 2023 Sep; 28(19):. PubMed ID: 37836603
[TBL] [Abstract][Full Text] [Related]
37. A novel compound to overcome influenza drug resistance in endonuclease inhibitors.
Ren Y; Wan L; Cao S
Mol Divers; 2023 Jun; ():1-11. PubMed ID: 37268742
[TBL] [Abstract][Full Text] [Related]
38. Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins.
Hou L; Zhang Y; Ju H; Cherukupalli S; Jia R; Zhang J; Huang B; Loregian A; Liu X; Zhan P
Acta Pharm Sin B; 2022 Apr; 12(4):1805-1824. PubMed ID: 35847499
[TBL] [Abstract][Full Text] [Related]
39. Recent Advances of Pyridinone in Medicinal Chemistry.
Lin S; Liu C; Zhao X; Han X; Li X; Ye Y; Li Z
Front Chem; 2022; 10():869860. PubMed ID: 35402370
[TBL] [Abstract][Full Text] [Related]
40. Drug Repurposing for Influenza Virus Polymerase Acidic (PA) Endonuclease Inhibitor.
Meng X; Wang Y
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
